<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46888">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01883427</url>
  </required_header>
  <id_info>
    <org_study_id>GObarn2013</org_study_id>
    <nct_id>NCT01883427</nct_id>
  </id_info>
  <brief_title>Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children</brief_title>
  <official_title>Placebo Controlled Study Among Children Below Four Years of Age, Investigating Whether a Glucose Oxidase Nasal Spray Can Reduce Days With Upper Respiratory Tract Infection Symptoms and Episodes of Otitis Media</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krister Tano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Umeå University</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate if use of glucosoxidas nasal spray can reduce the number of days with
      rhinitis and/or otitis in children beyond 4 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children below 4 years of age and in public day care were invited to participate in this
      prospective study. The children started with a visit to an ENT doctor and after inclusion
      the children started to spray twice daily with glucose oxidase+glucose or only
      saline+glucose for 3 months. During this period the parents were asked to fill in a home
      protocol recording upper respiratory tract symptoms as: rhinitis, cough, fever, ear ache.
      The parent were told to go to the ENT department if they suspected an episode of acute
      otitis media. After 6 weeks and 12 weeks the children had scheduled visits to the ENT
      department. After 12 weeks of treatment a nasopharyngeal swab was taken for bacterial
      culture.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Does a nasal spray with glucose oxidase reduce number of days with upper respiratory infectious symptoms and/or episodes of acute otitis media?</measure>
    <time_frame>3 months of recording</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Upper respiratory tract infection symptoms during a 3 months period are recorded in a home protocol by the parents of the children.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Upper Respiratory Tract Infections</condition>
  <condition>Acute Otitis Media</condition>
  <arm_group>
    <arm_group_label>Saline+glucose nasal spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nasal spray with saline+glucose twice daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nasal spray with glucose oxidase+glucose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nasal spray in a bag-on-valve device with 50U/ml glucose oxidase + 5% glucose in isotone saline. Dosage: One puff in each nostril twice daily for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucose oxidase</intervention_name>
    <description>Glucose oxidase is a hydrogen peroxide producing enzyme, imitating the inhibitory effects of the normal bacterial flora of the nasopharynx</description>
    <arm_group_label>Nasal spray with glucose oxidase+glucose</arm_group_label>
    <other_name>Nasal spray containing isotonic saline+glucose oxidase+5% glucose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline + glucose</intervention_name>
    <description>A bag on valve nasal spray device containing isotone saline and 5% glucose</description>
    <arm_group_label>Saline+glucose nasal spray</arm_group_label>
    <other_name>Nasal spray containing isotonic saline+5% glucose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children below 4 years of age

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Westman, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Västernorrlands Landsting</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie Ryding, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Jämtlands Landsting</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anders Niklasson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Norrbottens Landsting</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helena Toolanen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Norrbottens Landsting</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Öronmottagningen</name>
      <address>
        <city>Piteå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Öronmottagningen</name>
      <address>
        <city>Sunderbyn</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Öronmottagningen</name>
      <address>
        <city>Sundsvall</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Öronmottagningen</name>
      <address>
        <city>Östersund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 24, 2013</lastchanged_date>
  <firstreceived_date>April 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Umeå University</investigator_affiliation>
    <investigator_full_name>Krister Tano</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Days with URTI symptoms</keyword>
  <keyword>episodes of AOM</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
